Vaxcyte, Inc.
PCVX
Rank in Stocks
#2068
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Share Price
$65.50
Market Cap
$10.05B
Change (1 day)
2.95%
Change (1 year)
54.51%
Country
US
Trade Vaxcyte, Inc. (PCVX)
Category
Healthcare
Stock split history for Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. stock (symbol: PCVX) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 19, 2026.
One PCVX share bought prior to Oct 19, 2026 would equal to 0 PCVX shares today.
The most recent stock split occurred on Oct 19, 2026.
One PCVX share bought prior to Oct 19, 2026 would equal to 0 PCVX shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
